Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-l

• Status: NOT_YET_RECRUITING
• Trial end date: 2027-06-30

Summary

To evaluate the efficacy and safety of liposome irinotecan combined with platinum and immune checkpoint inhibitor combined with antirotinib maintenance therapy after first-line induction

• Phase: PHASE4

Details

• Lead Sponsor: China Medical University, China
• Treatments: anlotinib; Carboplatin; Cisplatin; Immune Checkpoint Inhibitors; Platinum; tislelizumab